Restructuring Global Liquidity: Structural Opportunities from US Defense to Yield-Bearing ETFs
Global Report·- Amid ongoing geopolitical fragmentation and expectations of liquidity, capital is quietly shifting towards defensive sectors and specific catalysts. - Recent trades indicate that investors are avoiding traditional large-cap tech stocks in favor of special purpose assets to seek absolute returns in an uncertain macro environment. - As policymakers grapple with interest rate decisions, the performance of various assets will be closely linked to upcoming macro data and cross-border tariff policies.Analyst Reiterates Buy on Caribou, Citing Strong vispa-cel Data and Pivotal ANTLER-3 Upside; Price Target Maintained at $11
Tip Ranks·- Analyst Robert Burns from H.C. Wainwright reiterated a buy rating on Caribou Biosciences, setting a target price of $11.00. - His endorsement is based on favorable data from the ANTLER trial, which showed an 82% overall response rate for the optimized vispa-cel (CB-010) treatment among a small cohort. - Burns emphasized significant potential for vispa-cel due to its characteristics and the upcoming ANTLER-3 study, while Bank of America also maintains a buy rating with a $6.00 target price.Caribou Biosciences: Buy Rating Reaffirmed on Advancing Allogeneic CAR-T Pipeline and EHA Data; $6 Price Target Maintained
Tip Ranks·- Bank of America analyst Alec Stranahan maintained a buy rating on Caribou Biosciences, setting a target price of $6.00. - This recommendation is based on the promising updates related to Caribou's allogeneic CAR-T product pipeline, particularly the strong response rates for vispa-cel in B-cell lymphoma. - Stranahan anticipates that the current stock price may rise as clinical validation continues, especially in light of upcoming catalysts post-EHA.